↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Parabilis Medicines$PBLS · filed: 🫧 Edgar looked up Parabilis MedicinesCheck ▾Close ▴
What Parabilis Medicines filed
🫧 Edgar looked up Parabilis Medicines, Inc. ($PBLS). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-11-05. 6 event filings (8-K) in the past twelve months. Every figure links to the filing it came from on Parabilis Medicines’s card.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
First genomics IPO above **$500M** in two years; tests whether biotech window reopens or Parabilis is an outlier.
$770.5 million
the largest capital raise for a genomics-focused company since…
$555 million
debut in December 2021
38.5 million
shares at
$20
per share
Parabilis Medicines priced its initial public offering at $770.5 million, the largest capital raise for a genomics-focused company since AbCellera's $555 million debut in December 2021. The company sold 38.5 million shares at $20 per share, the top of its revised range, according to filings reviewed Thursday morning. Underwriters have a standard 30-day greenshoe option for an additional 5.8 million shares, which could push total proceeds past $886 million.
The pricing came without warning. Parabilis had quietly amended its S-1 on Monday, raising the proposed range from $16-$18 to $19-$21 after what sources describe as oversubscription from life sciences-focused crossover funds. Lead bookrunners Goldman Sachs and Morgan Stanley allocated roughly 62% of the offering to long-only institutional accounts, with the remainder split between healthcare-specialist hedge funds and a small tranche reserved for strategic corporate investors. Trading begins Friday on Nasdaq under ticker PARA.
The deal matters because it reopens a window that's been nailed shut. Biotech IPOs raised just $3.2 billion in 2023, down 74% from the $12.4 billion raised in 2021, per Renaissance Capital. Parabilis is the first genomics platform to clear $500 million in nearly two years, and the first to price above range in that category since the Fed began tightening. The company's pre-money valuation of approximately $2.8 billion values it at 14x its last private round in June 2023, when it raised $180 million at a $200 million post-money from Arch Venture Partners and a16z Bio. That multiple compression from private to public—common in 2021—has been absent in recent biotech listings, most of which priced flat or down.
Parabilis develops gene-editing platforms for rare metabolic disorders, with three programs in Phase 1 and a disclosed pipeline targeting 12 genetic conditions with fewer than 50,000 diagnosed patients globally. The company has no revenue, burned $142 million in the twelve months ending September 2024, and projects a cash runway extending into Q3 2027 with the new capital. What it does have: exclusive licensing agreements with two top-ten pharma companies for undisclosed indications, and a platform that cuts CRISPR editing time from 72 hours to under 6 hours in preclinical models, per its S-1.
Allocators should track three follow-on events. First, whether the stock holds its IPO price through the 180-day lockup expiration in late May 2025—a test of whether this capital is patient or simply rotating out of illiquid VC positions. Second, Parabilis is expected to release interim Phase 1 data for its lead program, PBM-101, in Q2 2025; that readout will set the valuation framework for the next wave of gene-editing companies considering public markets. Third, watch for amendments to the two undisclosed pharma partnerships, which account for $420 million in potential milestones but no upfront economics—a structure that suggests the partnerships were struck before this IPO momentum materialized.
The pricing also clarifies what kind of biotech can still access growth capital. Parabilis is not a platform play with Nobel-adjacent science and a vague development timeline. It has defined programs, binary clinical catalysts within 18 months, and a management team that includes former Biogen and Vertex executives who've taken drugs through FDA approval. The market is buying execution risk, not concept risk. That's the line.
Branded by POPS4 · proof in 60 seconds
For the principal
Monitor Phase 1 data release in Q2 2025; positive readout could revalue entire gene-editing portfolio exposure.
For the operator
Watch lockup expiration behavior in May 2025 to gauge crossover fund conviction versus private exit liquidity.
For the house
Evaluating 2-3% allocation in named genomics strategy; awaiting post-IPO volatility settlement before entry.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.